Latest / Inside Startup Investing with Chris Lustrino
Inside Oxeia Biopharma’s Mission to Heal Brain Damage From Concussions
On this episode of Inside Startup Investing, Chris Lustrino speaks with Dr. Michael Wyand, CEO of Oxeia Biopharma, a clinical-stage biotech company developing a potential breakthrough treatment for concussions and persistent concussion symptoms.
Oxeia is leveraging ghrelin, a naturally occurring hormone involved in brain energy regulation and neural repair, to help heal the inflammation and cellular damage caused by traumatic brain injuries. With promising Phase 2a data showing an 85% responder rate among treated patients, the company is pursuing what could become the first FDA-approved…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.